Cardiovascular diseases (CVDs) identified as a serious public health problem. Although there is a lot of evidence that inflammatory processes play a significant role in the progression of CVDs, however, the precise mechanism is not fully understood. Nevertheless, recent studies have focused on inflammation and its related agents. Nucleotide oligomerization domain‐, leucine‐rich repeat‐, and pyrin domain‐containing protein 3 (NLRP3) is a type of pattern recognition receptor (PRR) that can recognize pathogen‐associated molecular patterns and trigger innate immune response. NLRP3 is a component of the NOD‐like receptor (NLR) family and have a pivotal role in detecting damage to cardiovascular tissue. It is suggested that activation of NLRP3 inflammasome leads to initiating and propagating the inflammatory response in cardiomyopathy. So, late investigations have highlighted the NLRP3 inflammasome activation in various forms of cardiomyopathy. On the other side, it was shown that noncoding RNAs (ncRNAs), particularly, microRNAs, lncRNAs, and circRNAs possess a regulatory function in the immune system's inflammatory response, implicating their involvement in various inflammatory disorders. In addition, their role in different cardiomyopathies was indicated in recent studies. This review article provides a summary of recent advancements focusing on the function of the NLRP3 inflammasome in common CVDs, especially cardiomyopathy, while also discussing the therapeutic potential of inhibiting the NLRP3 inflammasome regulated by ncRNAs. Significance statement: NLRP3 has been recognized as a crucial participant in the detection of cardiovascular tissue injury, hence beginning and propagating inflammatory responses in cardiomyopathy. Recent research has elucidated the complex relationship between the NLRP3 inflammasome and ncRNAs in the context of cardiomyopathies. Simultaneously, ncRNAs, including miRNAs, lncRNAs, and circRNAs, have garnered acknowledgment due to their regulatory functions in immune system‐mediated inflammatory responses and their implications in diverse inflammatory illnesses. Recent studies have also unveiled their participation in several forms of cardiomyopathies. Our study addresses the knowledge gap regarding the complex interplay among inflammation, the NLRP3 inflammasome, and ncRNAs in cardiomyopathies, hence presenting potential opportunities for therapeutic approaches in the field of cardiovascular disorders. [ABSTRACT FROM AUTHOR]